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Abstract
Background:  Renal cell carcinomas (RCC) are among the most common and most lethal
genitourinary malignancies. GOLPH2 (golgi phosphoprotein 2, GOLM1) has recently been
proposed as a biomarker for hepatocellular and prostate cancer. In this study we analysed the
expression patterns and the prognostic and diagnostic value of GOLPH2 in RCC.
Methods: GOLPH2 protein expression was analysed by immunohistochemistry in 104 clinically
well characterized RCC cases in comparison with matched normal kidney tissue and in association
with clinico-pathological parameters. Statistical analyses including Kaplan Meier analyses were
performed with SPSS version 15.0.
Results: GOLPH2 was highly expressed in normal renal tubules and in almost half of RCC with a
statistically significant predominance in the papillary and chromophobe histological subtypes. No
other associations with clinico-pathological parameters were detectable. The Kaplan-Meier curves
showed a weak trend for unfavourable prognosis of tumours with high GOLPH2 expression, but
failed significance.
Conclusion: GOLPH2 protein is expressed in normal renal tissue (especially in distal tubular
epithelia) and is down-regulated in the majority of clear cell RCC. In papillary and chromophobe
RCC GOLPH2 expression is consistently present. In contrast to its diagnostic value in
hepatocellular and prostatic carcinomas, a prognostic or diagnostic value of GOLPH2 in RCC
appears to be unlikely.
Background
Renal cell cancer (RCC) is one of the most common geni-
tourinary malignancies and causes of cancer associated
death in the United States of America in 2008 [1].
Although conventional tumour parameters like nodal sta-
tus, existence of systemic metastasis or pT-status are
important prognostic factors, new molecular markers are
warranted to provide more information on the tumour
biology, allowing for a better prognostic and possibly pre-
dictive stratification of patients.
GOLPH2 is a golgi phosphoprotein (also known as
GP73) of yet unknown function. The 73 kDa Golgi appa-
ratus associated protein is coded by the GOLM1 gene on
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chromosome 9q21.33, first described by Kladney et al. in
liver tissue of a patient with giant-cell hepatitis [2]. Struc-
turally, GOLPH2 protein has of a short cytoplasmic N-ter-
minal domain, a membrane-spanning region, some
coiled-coil domains and a longer luminal C-terminal
domain. The structure includes several areas of possible
glycosylation. Due to its localisation at the Golgi appartus
the proposed functions include protein modification, cell
signalling, intracellular transporting function or mere
local structural tasks.
Until now only few studies on GOLPH2 exist. In liver dis-
eases GOLPH2 has been described as a potential serum
marker of hepatocellular carcinoma [2-6]. Recently
GOLPH2 mRNA has been described in a marker combina-
tion to detect prostate cancer from urine samples and
soon afterwards two independent studies described
GOLPH2 as a prostate cancer tissue marker [7-9].
In this study, we carefully analysed the GOLPH2 protein
expression in a well characterized renal cell cancer cohort
with matched normal tissue. Central aim was to evaluate
the potential diagnostic and prognostic value of GOLPH2.
We found GOLPH2 differentially expressed between nor-
mal and malignant renal tissue and between the different
RCC subtypes, but a prognostic value could not be
detected.
Methods
Patients
One-hundred-four patients (81 men, 23 women) diag-
nosed for renal cancer at the Institute of Pathology, Char-
ité – Universitätsmedizin Berlin between 2003 and 2005
were enclosed in this study. The study has been approved
by the Charité University Ethics Committee under the title
"Retrospective Untersuchungen von Gewebeproben mit-
tels immunhistochemischer Färbung und molekularbiol-
ogischer Methoden" ("Retrospective analysis of tissue
samples by immunohistochemistry and molecular bio-
logical methods" (EA1/06/2004) on 20th  September
2004.
Patient age ranged between 28 and 92 years with a median
of 62. Histological diagnosis was established according to
the guidelines of the World Health Organization. Cases
were selected according to tissue availability and were not
stratified for any known preoperative or pathological
prognostic factor. 83 (79.8%) patients had a clear cell
RCC (ccRCC), 16 (15.4) a papillary RCC and 5 (4.8%) a
chromophobe RCC. Twenty-one patients had systemic
disease (M1) at the time of diagnosis. Clinical follow-up
data, as annually assessed survival time was available for
all patients. The median follow-up time of all cases was 30
months, ranging from one to 47 months. 21 of the
patients died from renal cancer. The pT status was as fol-
lows: pT1 – 53 (51.0%), pT2 – 3 (2.9%), pT3 – 45 (43.3)
and pT4 – 3 (2.9%). Ten patients (9.6%) had pathologi-
cally confirmed nodal metastases (pN1 = 2, pN2 = 8). 50
(48.1%) patients had no nodal metastases (pN0). For 44
(42.3%) patients no lymph nodes were histologically
examined (pNx). Tumour grades were G1 – 11 (10.6%),
G2 – 74 (71.2%), G3 – 15 (14.4%) and G4 – 4 (3.8%)
respectively.
Tissue Micro Array construction
A tissue-micro-array (TMA) was constructed to represent
108 cases, as previously described [10,11]. The tissue
arrayer was purchased from Beecher Instruments (Wood-
land, USA). The punch diameter was 0.6 mm with each
case being represented by two tumour and two normal
kidney cores. Four cases were lost during immunohisto-
chemistry processing. All statistical analyses were per-
formed using the 104 cases with GOLPH2 staining
available. Matched normal kidney tissue was available for
97 cases.
Immunohistochemistry
The TMA blocks were freshly cut (3 μm) and mounted on
superfrost slides (Menzel Gläser). Immunohistochemistry
was conducted with the Ventana Benchmark automated
staining system (Ventana Medical Systems, Tucson, AZ)
using Ventana reagents for the entire procedure. To detect
GOLPH2, a commercially available antibody (mouse
monoclonal, clone 5B10, Abnova Corporation, Taipei,
Taiwan, catalog number H00051280-M06, dilution
1:1000 was diluted in a Ventana diluent. For primary anti-
body detection we used the UltraVIEW™ DAB detection kit
using the benchmarks CC1m-heat induced epitope
retrieval. Slides were counterstained with hematoxylin,
dehydrated and mounted.
Evaluation of the immunohistochemical stainings
The immunostainings were evaluated by two genitouri-
nary pathologists at a multiheaded microscope. The stain-
ing intensity was determined by the two pathologists
using a four-tier grading system (0 = negative, 1 = weak, 2
= moderate and 3 = strong staining intensity). To achieve
a greater uniformity of the evaluation, the first step was to
construct a panel with four illustrative examples pictures,
of which a hardcopy lay next to the microscope. We used
a 10% threshold to determine positivity, irrespective of
the intensity grade. Only tumours without any GOLPH2
immunoreactivity or with staining of less than 10% of the
tumour cells were considered negative. To delineate
between low and high levels of GOLPH2 expression,
tumours with moderate to strong GOLPH2 expression
(2&3) and tumours with none to weak (0&1) staining
intensity were lumped.
Statistical analysis
Statistical analysis was performed using SPSS, version
15.0. Fisher's exact test, χ2-tests were applied to assess theBMC Urology 2008, 8:15 http://www.biomedcentral.com/1471-2490/8/15
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statistical significance of the associations between
GOLPH2 expression and clinico-pathological parameters.
Univariate survival analysis was carried out according to
Kaplan-Meier, differences in survival curves were assessed
with the Log rank test. P values < 0.05 were considered sig-
nificant.
Results
GOLPH2 immunostaining was easy to evaluate with the
typical cytoplasmic and in most cases perinuclear accentu-
ated staining pattern. In normal renal tissue we detected
GOLPH2 with its characteristic fine granular staining pat-
tern more often and with a stronger staining intensity in
the distal tubules than in proximal tubules (Figure 1). For
97 cases matching normal renal tissue was evaluated.
None of these cases were completely negative for
GOLPH2, 8 cases were scored 1+ and 89 cases 2+. Renal
glomeruli were often completely negative or displayed
only few cells with weak to moderate positivity.
Staining intensities of GOLPH2 in RCC were: negative –
29 (27.9%), 1+ – 30 (28.8%), 2+ – 34 (31.5%) and 3+ –
11 (10.6%). GOLPH2 positivity was significantly higher
in papillary and chromophobe RCC if compared to clear
cell RCC (Table 1, Figure 2). Other associations or corre-
lations (data not shown) with clinico-pathological
parameters could not be detected.
The univariate survival analyses demonstrated highly sig-
nificant p-values for the established tumour markers pT-
status, Fuhrman grade, nodal status and distant metastasis
(Table 2). Gender and age were no prognosticators for
patient survival (data not shown). For GOLPH2 there was
no statistically significant prognostic value for patient sur-
vival detectable (Table 2), although in the Kaplan-Meier
curve a weak trend for longer survival times of patients
with GOLPH2 negative tumours was apparent (Figure 3).
Importantly, it nearly reached significance (p = 0.057) in
the subgroup of clear cell RCCs.
Discussion
This study describes for the first time the expression pat-
tern of GOLPH2 in normal renal tissue and renal cell can-
GOLPH2 immunohistochemistry in renal cell carcinomas Figure 2
GOLPH2 immunohistochemistry in renal cell carci-
nomas. GOLPH2 expression in clear cell RCC with a nega-
tive (A) and a strongly positive (B) case. All chromophobe 
(C) and the vast majority of the papillary RCC (D) were dis-
played strong immunohistochemial GOLPH2 stainings.
A
C C
B
GOLPH2 immunohistochemistry in normal renal tissue Figure 1
GOLPH2 immunohistochemistry in normal renal tissue. A/B GOLPH2 expression in normal renal tissue with the typ-
ical perinuclear granular staining pattern being more prominent in the distal tubules, although occasionally proximal tubules 
(star) were also strongly positive (A). Staining with Tamm-Horsfall protein in a subsequent tissue section validates the localiza-
tion of GOLPH2 (B).BMC Urology 2008, 8:15 http://www.biomedcentral.com/1471-2490/8/15
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cer. GOLPH2 has been described in a variety of tissues,
but the most promising results until now have been dem-
onstrated in liver and prostate tissue [2,4,12]. In prostate
cancer GOLPH2 is up-regulated on mRNA and protein
level in comparison to the normal glandular tissue
[8,9,12,13]. In renal cell cancer, this seems not to be the
case and the high GOLPH2 expression in normal tissue
argues against a use oft this marker for the diagnosis of
RCC in histological samples. Whether GOLPH2 levels in
serum of RCC patients differ from those of healthy
patients has not been tested yet. Further studies of
GOLPH2 expression in RCC might focus on its meaning
for the different histological subtypes, since our results
suggest a different regulation in three most common types
of RCC. However, in the present study we did not include
any benign renal tumours or other rare histologic types of
RCC like sarcomatoid or rhabdoid RCC. We could not
detect any associations with conventional tumour and
clinical parameters. Since this study cohort was of
medium size with most of the cases being clear cell RCC
this study cohort was too small to detect a possible prog-
nostic value or subtle clinico-pathological associations for
chromophobe and papillary RCC. Still, the different
expression patterns of GOLPH2 in the three RCC subtypes
were surprising. Especially the difference between papil-
lary and clear cell carcinomas is notable since generally
both were thought to be derived from the proximal
tubules of the kidney. Given the strong expression of
GOLPH2 in normal renal epithelia, two possible explana-
tions for the GOLPH2 down-regulation are possible.
GOLPH2 expression might either be lost early in clear cell
carcinogenesis and re-expression of GOLPH2 could repre-
sent a molecular correlate of tumour de-differentiation.
This could explain the pronounced trend in the Kaplan
Meier curve of clear cell RCC, which nearly reached statis-
tical significance. On the other hand there was no positive
association with the Fuhrman grade. Very recently, Wright
et al. provided evidence for a relevant role of GOLPH2 for
the integrity of renal and hepatic tissues in a mouse model
with expression of a truncated GOLPH2 form [14].
Table 1: Associations (χ2-tests) between the protein expression GOLPH2 in renal cell cancer and clinico-pathological parameters 
(percentages in brackets)
Total GOLPH2 low* GOLPH2 high* p-value
All cases 104 (100) 59 (56.7)* 45 (43.3)*
Gender 0.475
men 81 (77.9) 44 (54.3) 37 (45.7)
women 23 (22.1) 15 (65.2) 8 (34.8)
Age 0.236
≤ 62 56 (53.8) 35 (62.5) 21 (37.5)
>62 48 (46.2) 24 (50.0) 24 (50.0)
Histology <0.001
clear cell 83 (79.8) 58 (69.9) 25 (29.1)
chromophobe 5 (4.8) 0 (0.0) 5 (100.0)
papillary 16 (15.4) 1 (6.3) 15 (93.7)
pT-status 1.000
pT1 53 (51.0) 30 (56.6) 23 (43.4)
pT2/3/4 51 (49.0) 29 (56.9) 22 (43.1)
pN-status 0.455
pN0 50 (48.1) 30 (60.0) 20 (40.0)
pN1 10 (9.6) 6 (60.0) 4 (40.0)
pNx 44 (42.3) 23 (52.3) 21 (47.7)
Fuhrman grade 0.347
G 1 11 (10.6) 8 (72.7) 3 (27.3)
G 2 74 (71.2) 41 (55.4) 33 (44.6)
G 3/4 19 (18.2) 10 (52.6) 9 (47.4)
Metastasis 0.389
M0/x 83 (79.8) 46 (55.4) 37 (44.6)
M1 21 (20.2) 13 (61.9) 8 (38.1)BMC Urology 2008, 8:15 http://www.biomedcentral.com/1471-2490/8/15
Page 5 of 6
(page number not for citation purposes)
In hepatocellular carcinoma (HCC), GOLPH2 had higher
serum levels if compared to healthy individuals and has
been proposed as a novel serum marker of HCC [6,15].
However, since GOLPH2 expression in a liver cell line
could also be up-regulated by viral (adenovirus) infection,
it seems reasonable to assume that either an inflammatory
a neoplastic process might be able to trigger GOLPH2
expression in this tissue type [5,16].
Even though in a previous study from our study group
(manuscript in preparation) we were able to confirm the
GOLPH2 expression in HCC, we also detected GOLPH2
in various other malignancies on a multi-tissue-micro-
array which argues against a liver-specific relevance of this
biomarker.
In summary, this first systematic analysis of GOLPH2 in
renal cell cancer describes that GOLPH2 expression is not
restricted to liver or prostate cancer but is also found in a
higher proportion of RCC, although no direct diagnostic
or prognostic value of GOLPH2 as a tissue biomarker
could be confirmed.
Conclusion
In this tissue-micro-array-based immunohistochemistry
study a differential expression of GOLPH2 in normal and
malignant renal tissue was demonstrated. While distal
tubular epithelia were mainly strongly positive for this
Table 2: Univariate survival analysis (Kaplan-Meier)
Characteristic No. of cases No. of events Two-year survival rate (± SE) in % p-value
GOLPH2 expression 0.162
low 59 9 86.4 ± 4.5
high 45 12 73.3 ± 6.6
pT-status < 0.001
pT1 53 2 96.3 ± 2.6
pT2/3/4 51 19 64.7 ± 6.7
Fuhrman grade 0.001
G 1 11 0 -
G 2 73 12 84.9 ± 4.2
G 3/4 19 9 52.6 ± 11.5
pN-status 0.001
pN0 50 10 80.0 ± 5.7
pN1+ 10 7 40.0 ± 15.5
Metastasis < 0.001
M0 83 8 90.4 ± 3.2
M1 21 13 42.9 ± 10.8
Survival times of patients with renal cell cancer according to clinico-pathological characteristics and GOLPH2 protein expression.
Kaplan-Meier survival curve for GOLPH2 Figure 3
Kaplan-Meier survival curve for GOLPH2. Tumours 
with high GOLPH2 expression (bold line) revealed a slight 
but insignificant trend for shortened patient survival times if 
compared to those with low GOLPH2 expression (dotted 
line). The number of cases/events (deaths) is given in brack-
ets.
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marker, other parts of the nephron and the majority of the
clear cell RCC were negative. The diagnostic use of the
rather constant positivity of papillary and chromophobe
RCC is limited since one third of the clear cell carcinomas
were also positive for GOLPH2. No other associations
with conventional clinico-pathological characteristics
were found and no prognostic value of GOLPH2 was
demonstrated which limits the diagnostic value of
GOLPH2 in RCC.
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